Algorae Signs Non-Binding Umedica MOU for Eight Australian Molecules

Algorae signs MOU and Licence & Supply Agreement with Umedica for Australia

Through its wholly owned subsidiary AlgoraeRx Pty Ltd, Algorae Pharmaceuticals (ASX: 1AI) has entered into two separate agreements with Umedica Laboratories Pvt. Limited for the Australian pharmaceutical market, as announced on 19 October 2026. The agreements are a non-binding Memorandum of Understanding (MOU) and a separate, binding Licence & Supply Agreement (LSA).

The agreements add to the AlgoraeRx pipeline and relate to the commercialisation side of the business. Key points from the announcement:

• AlgoraeRx executed a non-binding MOU and a separate, binding LSA with Umedica.
• Under the MOU, AlgoraeRx is appointed as Umedica’s exclusive importer, distributor and commercial partner in Australia across eight molecules.
• Under the LSA, the product’s dossier has been submitted to the Therapeutic Goods Administration (TGA) for regulatory approval.
• Financial terms of the LSA are commercial-in-confidence.

Two agreements, two structures

MOU covers eight molecules

Under the non-binding MOU, AlgoraeRx is appointed as Umedica’s “exclusive importer, distributor and commercial partner” in Australia across a portfolio of eight molecules. Exclusivity applies specifically to Umedica-branded (sponsored) products only.

Umedica acts as manufacturer and Marketing Authorisation Holder. The MOU sets out the framework for the collaboration, with definitive agreements to be negotiated in due course. As the MOU is non-binding, those definitive agreements are yet to be settled.

The exclusive Zydus agreement covering 10 products across Australia and New Zealand shows the same partner-led model, in which AlgoraeRx builds a multi-product portfolio without carrying its own manufacturing costs.

LSA puts a product on the TGA pathway

The binding LSA is a standalone licence and supply arrangement. Umedica licenses its dossier and know-how and will supply the product, while AlgoraeRx obtains the marketing authorisation and commercialises the product under its own brand in Australia.

The LSA product’s dossier has been submitted to the TGA, and further molecules are under evaluation for additional licence and supply arrangements. The financial terms of the LSA are commercial-in-confidence, so no value has been disclosed.

How generic pharmaceutical licensing and supply works

A dossier is the body of documentation supporting a medicine’s quality, safety and efficacy. A Marketing Authorisation Holder is the entity that holds the regulatory authorisation to market a medicine. The TGA is the Australian regulator that assesses therapeutic goods.

In simple terms, the pathway involves three steps:

1. A manufacturer prepares a dossier for the product.
2. The dossier is submitted to the TGA for regulatory approval.
3. Once authorisation is obtained, the holder of the marketing authorisation can commercialise the product.

The two agreements differ on this point. Under the MOU, AlgoraeRx acts for Umedica-branded (sponsored) products, with Umedica as Marketing Authorisation Holder. Under the LSA, AlgoraeRx obtains the marketing authorisation and commercialises the product under its own brand.

Own-brand registration may give AlgoraeRx more control over its product portfolio. Approval, however, is not guaranteed, and the announcement’s forward-looking statements note that there is no assurance any regulatory filing will satisfy TGA requirements.

Why Umedica’s manufacturing credentials matter

Umedica is a vertically integrated Indian pharmaceutical company headquartered in Mumbai. It manufactures active pharmaceutical ingredients (APIs) through its API arm, Amoli Organics, as well as finished dosage forms in-house.

Both its API and finished-product plants are approved by:

• The United States Food and Drug Administration (FDA)
• The European Union
• The United Kingdom
• TGA Australia
• Health Canada

Algorae Executive Chairman David Hainsworth highlighted the standing of the partner.

David Hainsworth, Executive Chairman

“…partnering with a company of that standing is a strong endorsement of AlgoraeRx…”

AlgoraeRx Managing Director Vishal Shah linked the agreements to the company’s pipeline strategy.

Vishal Shah, Managing Director, AlgoraeRx

“These agreements further enhance our product pipeline and strengthen our strategy to build a reliable, compliant portfolio of high-quality medicines for the Australian market.”

What to watch next

The announcement points to several developments that investors may follow:

• The TGA outcome on the LSA product’s dossier.
• Definitive agreements following the MOU.
• The outcome of the further molecules under evaluation for additional licence and supply arrangements.

The company stated it will update shareholders as these initiatives progress. No timelines were disclosed.

Algorae describes itself as an AI-enabled pharmaceutical company with a dual focus. Its AlgoraeOS platform applies machine learning to identify synergistic drug combinations, while AlgoraeRx sources, licenses and supplies generic and specialty medicines in Australia and New Zealand.

For readers wanting to explore the drug discovery side of the business, our deep-dive into AlgoraeOS v2 validation results covers the independent Peter MacCallum findings and the multi-anchor pipeline now underway.

Ready to Learn More About Algorae’s Umedica Agreements?

AlgoraeRx has signed a non-binding MOU covering eight molecules and a binding Licence & Supply Agreement with Umedica, with a dossier already submitted to the TGA. The deals add to a growing partner-led portfolio for the Australian pharmaceutical market.

Investors wanting to follow the company’s pipeline and upcoming milestones can visit the Algorae Pharmaceuticals website for further details. It is a useful starting point for understanding how AlgoraeRx plans to commercialise its medicines.